

Cumulative Index 2004

Volume 24

March	ENDOCRINE LABORATORY SCIENCE: TOPICS AT THE INTERFACE OF CLINICAL CARE AND LABORATORY MEDICINE, pages 1–328
June	ANTIMICROBIAL RESISTANCE: CHALLENGES AND SOLUTIONS, pages 329–558
September	EMERGING INFECTIONS AND THEIR CAUSATIVE AGENTS, pages 559–848
December	PATHOLOGY PATIENT SAFETY, pages 849–1064

Note: Page numbers of article titles are in **bold face** type.

A

- Acinetobacter*, antibiotic-resistant, in pediatric patients, 361
- Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection.
- Acromonium* infections, 700–701
- Addenda, for reporting results, 929–930
- Addison disease, 110–111
 autoantibodies in, 289–291
 in autoimmune polyglandular syndromes, 293–295, 305
 ovarian autoimmunity with, 292, 294
- Adherence to procedure, in point-of-care testing, 1003
- Adipocytes and adipocytokines, **217–234**
 adiponectin, 222–224, 229
 assays for, 228
 interleukin-6, 226–227, 229
 interleukin-8, 227
 leptin, 219–222, 229
 plasminogen activator inhibitor type 1, 225–226, 229
 resistin, 224, 229
 tumor necrosis factor- α , 224–225, 229
- Adiponectin, 222–224, 229
- Adipsin, in adipose tissue, 227
- Adrenal gland
 congenital hyperplasia of, 112–113
 hormones of, 106–107
 insufficiency of. *See* Addison disease.
- Adverse events
 definition of, 981, 998
 impact of, 1025
 in point-of-care testing, 1018
- Aeromonas* infections, 620–621
- African trypanosomiasis, 754–757
- Agar screen test, for methicillin susceptibility, 410
- Agency for Healthcare Research and Quality, Transforming Health Care Quality through Information Technology program of, 924–925
- AIDS. *See* Human immunodeficiency virus infection.
- Air travel, infection transmission in, 564
- AIRE protein. *See* Autoimmune regulator protein.
- Aldosterone, 106
 excess of, 109–110
 transport of, 108
- Alkaline phosphatase, bone, in osteoporosis, 187–188
- Alveolar echinococcosis, 828–829
- Ambler classification, of beta-lactamases, 345–346
- Amendments, for reporting results, 929–930
- American trypanosomiasis (Chagas' disease), 760–763, 813–814

- Amoxicillin**
for respiratory tract infections
distribution of, 486
dosing of, 485, 490, 492, 494
resistance to, 495
susceptibility testing of, 501-528
- Amoxicillin/clavulanate, 529-549**
development of, beta-lactam resistance and, 530-536
extended-release, 539-544
for pneumonia, 537-539, 541-544
for respiratory tract infections, 490-491
for rhinosinusitis, 536-537, 539-544
pharmacokinetics of, 540
resistance to, 495
susceptibility testing of, 501-528
- Amp C beta-lactamases**
(cephalosporinases), 346, 348-353
- Amphotericin B, resistance to, 723**
- Ampicillin, susceptibility testing of, 501-528**
- Analog direct immunoassay, for testosterone, 122-123**
- Analytic errors**
definition of, 981
detection and reduction of, 1026-1027
informatics for, 929-933
Q-PROBES and Q-TRACKS programs for, 972-974
frequency of, 1026
in point-of-care testing, 1006, 1008-1009, 1011
- Analytical isoelectric focusing, for beta-lactamase identification, 353**
- Anaplasma infections, 639-642, 811**
- Anatomic pathology, errors in, 849-863, 972-974**
definition of, 849-850
detection and reduction of
changing pathology practice due to, 857-858
conference review method for, 854-856
cytologic-histologic correlation method for, 851-854
lean production methods in. *See under* Lean production methods.
methods for, 850
root cause analysis for, 857
Web-based systems for, 858, 937-938
identification, 987-988
multi-institutional study of, 851
statistics on, 850
types of, 849-850
- Androgens, 107. *See also* Testosterone.**
priming with, for growth hormone testing, 155
transport of, 108-109
- Andropause, Leydig cell functional evaluation in, 126-130**
- Angiotensinogen, in adipose tissue, 227**
- Animals, infections due to. *See* Zoonoses.**
- Anthrax, as bioterrorism agent, 578**
- Antibiograms, for antibiotic therapy optimization, in critical illness, 331**
- Antibiotics, resistance to. *See* Antimicrobial resistance.**
- Antibody(ies). *See also* Autoimmune disorders; specific antibodies.**
heterophile, interfering with hormone immunoassays, 4-6, 35
monoclonal. *See* Monoclonal antibodies.
polyclonal, for thyroglobulin, 31-32
- Antifungal agents, resistance to, 721-735**
Aspergillus, 724-725, 728-729
at cell wall, 725-726
at cytoplasmic membrane, 723-725
Candida, 722-727
Cryptococcus neoformans, 723-727
definition of, 721-722
epidemiology of, 726-730
Fusarium, 729
Pneumocystis jiroveci, 725
Saccharomyces cerevisiae, 725
Scedosporium, 729-730
susceptibility testing methods for, 722
Trichosporon, 723, 727
Zygomycetes, 723
- Antigen detection methods, for *Toxoplasma gondii*, 742**
- Antimicrobial resistance. *See also***
Antifungal agents, resistance to; specific antibiotics.
in critical illness, 329-341
in emerging infections, 575-576
in Gram-negative bacteria, in hospitalized children, 361-378
in *Haemophilus influenzae*, 453-473, 501-528
in HIV, 773
in institutionalized elderly persons, 343-360
in *Moraxella catarrhalis*. *See Moraxella catarrhalis.*

- in respiratory pathogens
 - amoxicillin/clavulanate evolution for, **529-549**
 - mechanisms of, **417-451**
 - pharmacodynamics and pharmacokinetics of, **475-500**
 - in *Salmonella*, nontyphoidal, 611-612
 - in *Staphylococcus aureus*, 442
 - methicillin, **401-416**
 - vancomycin, **379-400**
 - in *Streptococcus pneumoniae*. See *Streptococcus pneumoniae*.
 - selection of, 423-426
 - Antiretroviral drugs, HIV resistance to, 773
 - APSs (autoimmune polyglandular/polyendocrine syndromes), 293-294, **305-317**
 - Arbovirus infections, geographical expansion of, 570-571
 - Arginine stimulation test, for growth hormone, 150-151, 153-155
 - Aspergillus* infections, 695-696, 698-699
 - resistance in, 724-725, 728-729
 - Association for Pathology Informatics, 920
 - Asthma
 - Chlamydophila pneumoniae* in, 635-636
 - Mycoplasma pneumoniae* in, 635-636
 - Atherosclerosis, *Chlamydophila pneumoniae* in, 637-638
 - Athletes, methicillin-resistant
 - Staphylococcus aureus* transmission among, 406-407
 - Atmospheric pressure photoionization, in liquid chromatography-mass spectrometry, for steroid hormones, 114-116
 - ATP-binding cassette transporter genes, in antifungal resistance, 724
 - Autoantibodies, interfering with hormone immunoassays, 6-7
 - Autoimmune disorders, **275-303**
 - Addison disease. See Addison disease.
 - celiac disease, 287-289
 - diabetes mellitus. See Diabetes mellitus.
 - lymphocytic hypophysitis, 295-296
 - ovarian, 291-292, 294
 - polyglandular, 292-295, **305-317**
 - thyroid, 284-287, 291-292, 305
 - Autoimmune regulator protein
 - distribution of, 307-308
 - functions of, 312-313
 - gene of, 307
 - mutations of, 308-314
 - structure of, 307
 - Avian influenza, human disease from, 574-575
 - Avidin-biotin-peroxidase method, for thyroglobulin, 31-33
 - Azithromycin
 - for respiratory tract infections
 - distribution of, 486
 - dosing of, 479-480
 - resistance to, 488
 - resistance to, 457, 461, 488, 495
 - susceptibility testing of, 501-528
 - Azoles, resistance to, 724-725
-
- B**
- Babesia* infections, 757-760, 812-813
 - Bacillus* infections, transfusion-transmitted, 809
 - Bacterial contamination, of blood components, 808-810
 - Bar codes, for identification, 927, 993-994, 1028
 - Baylisascaris procyonis* infections, 746-748
 - BBL Crystal MRSA ID System, for methicillin resistance, 412
 - Beef tapeworm infections, 766-768
 - Behavioral factors, in emerging infections, 563, 565-569
 - Beta-lactamases
 - Amp C type (cephalosporinases), 347-348
 - classification of, 345-346
 - description of, 344
 - extended spectrum, 346-351
 - Gram-negative bacteria, 361-362
 - Haemophilus influenzae*, 421-422, 434
 - inhibitors of, 435-436
 - molecular epidemiology of, 353-355
 - Moraxella catarrhalis*, 422, 434-435
 - nomenclature of, 344-345
 - non-SHV, 348
 - non-TEM, 348
 - respiratory tract pathogens,
 - mechanisms of, 427-436
 - Staphylococcus aureus*, in methicillin resistance, 403
 - Binding proteins, interfering in hormone immunoassays, 7-8

- Bio-Intact assay, for parathyroid hormone, 202-203
- Biometric patient identification systems, 992
- Bioprosthetic infections, coagulase-negative streptococcal, 592-593
- Biopsy
in cervical cancer, cytology comparison with, 953-955
in osteoporosis, 177
- Biosite immunofluorescent assay, for B-type natriuretic peptide, 262-264
- Bioterrorism, emerging infections due to, 563, 578
- Bipolaris* infections, 704
- Blastoschizomyces capitatus* infections, 707
- Blood banking
identification errors in, 983, 986-987
infections transmitted in. *See* Transfusion-transmitted infections.
specimen collection errors in, 971-972
- Blood culture, specimen collection for, errors in, 971
- Blood smear examination
for *Babesia*, 758-759
for malaria, 752-753
for *Trypanosoma brucei*, 756
for *Trypanosoma cruzi*, 762
- Body scan, in thyroid carcinoma, thyroglobulin assay with, 40-41
- Bone
biopsy of, in osteoporosis, 177
formation of, biochemical markers of, 187-190
resorption of, biochemical markers of, 179-187
- Bone alkaline phosphatase isoenzyme, in osteoporosis, 187-188
- Bone mineral density, measurement of, in osteoporosis, 177
- Bone sialoprotein, in osteoporosis, 180
- Borreliosis (Lyme disease), 810-811
- Bronchiolitis and bronchiolitis obliterans
Chlamydia pneumoniae in, 637
Mycoplasma pneumoniae in, 637
- Bronchoscopes, contaminated, in antibiotic resistance development, 335
- Broth microdilution, in susceptibility testing, for methicillin resistance, 410
- Burn patients, fungal infections in, 693
- Bush-Jacoby-Medeiros classification, of beta-lactamases, 345-346
-
- C**
- C cells, hyperplasia of, in medullary thyroid carcinoma, 51-52
- CA-125, immunoassay for, interference in, 12
- Calcitonin, in medullary thyroid carcinoma secretion of, 51
testing for, 66-68
- Calcium, urinary, in osteoporosis, 179
- Campylobacter* infections, 615-618
clinical features of, 616
diagnosis of, 616-617
epidemiology of, 615-616
microbiology of, 615
treatment of, 617-618
- Campylobacter jejuni* infections, water-borne, 568
- Cancer
cervical, screening for. *See* Cervical cancer screening.
fungal infections in, 695
- Cancer Checklists, College of American Pathologists, 914-915, 932-933
- Candida* infections, 694-696, 704-705
mucocutaneous, in autoimmune polyglandular syndromes, 293-294, 305
resistance in, 576, 722-727
- Candins, resistance to, 725
- Carcinoma, thyroid
medullary. *See* Medullary thyroid carcinoma.
thyroglobulin measurement in, 29, 31-32, 34, 38-42
- Cardiac arrhythmias, ventricular B-type natriuretic peptide in, assays for, 259
- Caspofungin, resistance to, 725
- Catecholamines, testing for, in pheochromocytoma
diagnostic value of, 86-89
versus metanephrines, 91-92
- Catheter-related infections
coagulase-negative streptococcal, 592-593
fungal, 693-694
- Cefaclor, susceptibility testing of, 501-528

- Cefdinir, susceptibility testing of, 501-528
- Cefixime, susceptibility testing of, 501-528
- Cefprozil, susceptibility testing of, 501-528
- Ceftazidime, resistance to, in institutionalized elderly persons, 346, 348-353
- Ceftriaxone
 resistance to, *Salmonella*, 612
 susceptibility testing of, 501-528
- Cefuroxime, susceptibility testing of, 501-528
- Celiac disease, 287-289
- Cell culture
 for filoviruses, 774
 for henipaviruses, 777
 for monkeypox, 779
- Cell wall, antifungal resistance involving, 725-726
- Cellulitis, *Streptococcus iniae*, 600
- Cephalosporin(s)
 resistance to, 346, 348-353, 495
 in *Streptococcus pneumoniae*, 420-421
 susceptibility testing of, 501-528
- Cephalosporinases (Amp C beta-lactamases), 345-348
- Cervical cancer screening
 error detection in, 852-854
 in developing countries, **945-963**
 appropriate management after, 953-956
 outcomes measurement in, 946-947
 quality management in, 945-949
 of cytology facilities, 950-953
 of noncytologic methods, 956-959
 target demographic groups in, 949-950
- Cervix, direct inspection of, in cancer screening, 956
- Chagas' disease (American trypanosomiasis), 760-763, 813-814
- Check digit technology, for identification, 992-993
- Chemiluminescent assays, for parathyroid hormone, 201
- Chemistry, identification errors in, 989-990
- Child care arrangements, emerging infections and, 566-567
- Chlamydomydia pneumoniae* infections, 633-635
 antibiotic therapy for, 490, 494
 asthma and, 635-636
 atherosclerosis and, 637-638
 bronchiolitis and bronchiolitis obliterans and, 637
 chronic obstructive pulmonary disease and, 636-637
 cystic fibrosis and, 637
 diagnosis of, 634-635
 multiple sclerosis and, 638
- Chloramphenicol, as protein synthesis inhibitor, 436
- Cholera, 606-608
 clinical features of, 607
 diagnosis of, 608
 epidemiology of, 606
 global warming and, 569
 microbiology of, 606
 non-01 type, 608-609
 transmission of, 564
 travel-associated, 568-569
 treatment of, 608
 water-borne, 568-569
- Chromatography
 for steroid hormones, 113
 gas, with mass spectrometry, for testosterone, 120
 high-performance liquid
 with electrochemical detection, for metanephrine, 88-89, 93-96
 with mass spectrometry
 atmospheric pressure photoionization, for steroid hormones, 114-116
 for metanephrine, 93-94, 96-100
 hydrophobic interaction, for insulin-like growth factor I, 159
 thin-layer, for mycobacteria, 652
- Chronic obstructive pulmonary disease
 Chlamydomydia pneumoniae in, 636-637
 Mycoplasma pneumoniae in, 636-637
- Ciprofloxacin, for respiratory tract infections
 distribution of, 486
 dosing of, 481-482
- Citrobacter*, antibiotic-resistant, in pediatric patients, 361
 colonization by, 370
 epidemiology of, 362-363

- Cladophialophora bantiana* infections, 704
- Clarithromycin
for respiratory tract infections
dosing of, 479-480
resistance to, 488
resistance to, 488, 495
susceptibility testing of, 501-528
- Climatic change, emerging infections and, 563, 569-571
- Clindamycin
resistance to, 457, 460, 495
susceptibility testing of, 501-528
- Clinical Context Object Workgroup, 915-916, 928-929
- Clinical Laboratory Improvement
Amendments of 1988
point-of-care testing regulations of, 998-1001, 1003-1004, 1011, 1015
purpose of, 1030
- Clonidine stimulation test, for growth hormone, 151, 153
- Colitis, hemorrhagic, in *Escherichia coli* O157:H7 infections, 613-614
- Collagen cross-links, in osteoporosis, 180, 182-187
- College of American Pathologists
Cancer Checklists of, 914-915, 932-933
Q-PROBES and Q-TRACKS
programs of. *See* Q-Probes and Q-TRACKS programs.
- Colorimetric methods, in metanephrine measurement, 90
- Communication. *See also* Reporting.
lack of, in health care system, errors resulting from, 1029
of laboratory data, 917
- Compensation, in heart failure, 238-241
- Competence assessment, in point-of-care testing, 1014
- Competitive immunoassays, for hormones, interferences in, 1-2
- Competitive radioreceptor assay, for thyroid-stimulating hormone receptor antibodies, 285-286
- Complement fixation test, for adrenal hormone antibodies, 290
- Computed tomography, for tapeworm infections, 768
- Concentration-dependent killing, by antibiotics, 480-481
- Conference review, for error detection, 854-855
- Congenital adrenal hyperplasia, 112-113
- Congestive heart failure. *See* Heart failure.
- Connectivity, in point-of-care results transfer, 1010
- Conn's syndrome, 109-110
- Context management, 915-916, 928-929
- Continuous workflow, in lean production, for error reduction, 883, 886-887, 889, 891-897
- COOH-terminal telopeptides, in osteoporosis, 181-185, 187
- CoPath Plus system, for reporting, 930-932
- Coronavirus infections (SARS), 576-577, 780-781, 803-804, 834-835
- Corticosteroids, 106-107
fungal infections due to, 696
thyroid function testing effects of, 26
- Corticotropin-stimulation test, for adrenal insufficiency, 111
- Cortisol, 106-107
excess of, in Cushing's syndrome, 111
measurement of, in adrenal insufficiency, 110-111
transport of, 108
- Creutzfeldt-Jacob disease, transfusion-transmitted, 814-817
- Critical illness
antibiotic-resistant infections in, 329-341
epidemiology of, 330
optimizing therapy for, 330-333
prevention of, 334-338
fungal infections in, 693
- "Crossing the Quality Chasm," 1024
- Cross-reactivity, in hormone immunoassays, 8
- Cryptococcus neoformans* infections, 694, 705-706
resistance in, 723-727
- Cryptosporidiosis, 568, 744-746
- Culture. *See also* Cell culture.
bacterial, in blood components, 810
blood, specimen collection for, errors in, 971

- Ehrlichia*, 642
fungal. *See specific fungi.*
urine, specimen collection for, errors in, 971
- Curvularia* infections, 704
- Cushing's syndrome, 111
- Cystic fibrosis
Chlamydomydia pneumoniae in, 637
Mycoplasma pneumoniae in, 637
- Cysticercosis, 766-768
- Cytochrome p450 side chain cleavage enzyme, antibodies to
in Addison disease, 290-291
in polyglandular syndrome, 306
- Cytokines, in adipose tissue. *See* Adipocytes and adipocytokines.
- Cytology
histology correlation with, for error detection, 851-854
identification errors in, 987-988
in cervical cancer screening. *See* Cervical cancer screening.
- Cytomegalovirus infections,
transfusion-transmitted, 801-802
- Cytoplasmic membrane, antifungal resistance involving, 723-725
-
- D**
- Dactylaria gallopavum* infections, 704
- Databases, for medical errors, 858
- Daycare, emerging infections in, 566-567
- Death, from infections, causes of, 560
- Decision support, in error detection and reduction, informatics for, 916, 927-928
- Dehydroepiandrosterone, 107
- Delta checks, for identification error detection, 984
- Dematiaceous mold infections, emerging, 704
- Demographic factors, in emerging infections, 562
- Dengue fever, 570, 808
- Deoxyypyridinoline, in osteoporosis, 181-183, 186
- Dexamethasone suppression test, in Cushing's syndrome, 111
- Diabetes mellitus, 275-284
autoantibodies in
glutamic acid decarboxylase, 280-281
ICA512 (IA-2), 281-282
in autoimmune polyglandular syndromes, 294-295, 305-306
insulin, 282-284
islet cell, 279-280
types of, 277-278
environmental triggers of, 276
genetic determinants of (HLAs), 276
types of, 275-276
- Diagnostic errors, in pathology. *See* Anatomic pathology, errors in.
- Dihydrotestosterone, 107
- Direct immunofluorescence, for islet cell antibodies, 279
- Disk diffusion test, for methicillin susceptibility, 410
- DNA
replication of, inhibitors of, in antibiotic resistance development, 441-443
translocation of, in antibiotic resistance development, 426
- DNA analysis
for identification error detection, 983
for monkeypox, 779
for pituitary hormone genes, 166
for Rickettsiae, 643
16S rDNA, for mycobacteria, 651
- DNA gyrase, inhibitors of, 441-442
- L-DOPA stimulation test, for growth hormone, 150-151, 153-154
- Doxycycline
resistance to, 495
susceptibility testing of, 501-528
- Dual-energy x-ray absorptiometry, in osteoporosis, 177
-
- E**
- Ebola virus infections, 773-774, 832-833
- Echinocandins, resistance to, 725
- Echinococcosis, alveolar, 828-829
- Efflux mechanism, in antibiotic resistance, 439-440, 442-443, 459
- Ehrlichia* infections, 639-642, 811

- Elderly persons
in institutions, antibiotic resistance in, **343-360**
beta-lactamases in, 344-348
ceftazidime, 346, 348-353
molecular epidemiology of, 353-355
surveillance for, 352
Leydig cell functional evaluation in, 126-130
thyroid function testing in, 24
- Electrochemiluminescent method
for B-type natriuretic peptide, 245
for parathyroid hormone, 201
- Electron microscopy, for microsporidia, 743
- Electronic medical records, 916-917
- Electrophoresis
for tartrate-resistant acid phosphatase, in osteoporosis, 180
pulsed-field gel, for beta-lactamase identification, 354
- Emerging infections. *See also specific infections.*
chronology of, 559-562
factors affecting, **559-586**
behavioral, 563, 565-569
bioterrorism, 563, 578
child care practices, 566-567
chronic manifestations of disease, 563, 571-572
demographic, 562-563
environmental change, 563, 569-571
food processing changes, 567-569
microbial evolution, 563, 574-576
pathogen detection methods, 563, 572-573
population distribution, 563-565
public health system breakdown, 563, 576-578
sexual behavior, 565-566
water supply contamination, 567-569
fungal, **691-719, 721-735**
gram-negative enteric, **605-626**
gram-positive, **587-603**
intracellular bacterial, **627-649**
mycobacterial, **651-690**
parasitic, **737-772**
resistant. *See* Antimicrobial resistance;
Antifungal agents, resistance to.
transfusion-related, 757-763, **797-823**
viral. *See* Viral infections, emerging.
zoonoses. *See* Zoonoses, emerging.
- Endocrine disorders
adipose tissue, **217-234**
autoantibodies in, **275-303**
autoimmune polyglandular, 292-295, **305-317**
growth hormone deficiency, **141-173**
immunoassays in, interferences in, **1-18**
natriuretic peptides, **235-274**
osteoporosis in, **175-197**
parathyroid hormone, **199-216**
pheochromocytoma, 61-63, **85-103**
steroid imbalance, **105-118**
testosterone abnormalities. *See* Testosterone.
thyroid carcinoma, **29-47, 49-83**
thyroid function, **19-28**
- Endomysial autoantibody assay, for transglutaminase antibodies, in celiac disease, 288
- Enteric infections, gram-negative. *See* Gram-negative bacteria, in emerging enteric infections.
- Enterobacter*, antibiotic-resistant, in pediatric patients, 361
colonization by, 369
epidemiology of, 362-363, 365
outbreaks of, 366
- Enterococci, vancomycin-resistant, 380-382
- Enterococcus faecium*,
vancomycin-resistant, 575
- Enterotoxins, *Staphylococcus aureus*, 407-408
- Enterovirus infections,
transfusion-transmitted, 804-805
- Entomophthorales infections, 701-702
- Environmental change, emerging infections and, 563, 569-571
- "Envisioning a National Health Care Quality Report," 1024-1025
- Enzyme immunoassay
for *Cryptosporidium parvum*, 745
for *Mycoplasma pneumoniae*, 632-633
for Rickettsiae, 645
for *Toxoplasma gondii*, 742
for West Nile virus, 783
- Enzyme-linked immunosorbent assay
for adipocytokines, 228
for glutamic acid decarboxylase antibodies, in diabetes mellitus, 280-281
for hantavirus, 776
for henipaviruses, 777

- for insulin antibodies, 283
 - for tapeworm infections, 768
 - for transglutaminase antibodies, in celiac disease, 288
 - Epinephrine, tumors secreting. *See* Pheochromocytoma.
 - Epstein-Barr virus infections, transfusion-transmitted, 801-802
 - Equilibrium dialysis/ultrafiltration, for testosterone assay, 122
 - ERG11* gene, in antifungal resistance, 724-725
 - erm* genes, in macrolide resistance, 411, 439, 454-458, 462-465
 - Error detection and reduction
 - barriers to, **901-911**
 - fear, 905-908
 - individual, 902-903
 - intolerance of uncertainty, 903-905
 - organizational structure and culture, 908-909
 - systems, 903
 - examination in, **849-863**
 - failure to report errors and, 903-905
 - frequency of errors and, 1025-1026
 - identification type, **979-996**
 - impact of, on patient care, 1025-1030
 - in cervical cancer screening, **945-963**
 - in point-of-care testing, **997-1022**
 - informatics in, **913-943**
 - Institute of Medicine reports on, 913-914, 935-937, 1023-1025
 - laboratory involvement in, **1023-1035**
 - lean production methods for, **865-899**
 - Q-PROBES and Q-TRACKS programs for, **965-978**
 - regulations on, 1030
 - voluntary programs for, 1030-1033
 - Erythromycin
 - for respiratory tract infections, 492, 494
 - mode of action of, 453
 - resistance to
 - epidemiology of, 462-463
 - in *Staphylococcus aureus*, 411
 - in *Streptococcus pneumoniae*, 421
 - mechanisms of, 457, 460
 - susceptibility testing of, 501-528
 - Escherichia coli* infections
 - antibiotic therapy for, 483
 - antibiotic-resistant, in pediatric patients, 364-365
 - O157:H7, 612-614
 - clinical features of, 613-614
 - diagnosis of, 614
 - epidemiology of, 613
 - food-borne and water-borne, 568
 - microbiology of, 612-613
 - treatment of, 614
 - transfusion-transmitted, 809
 - Estradiol, 108
 - Estrogen(s), 108
 - priming with, for growth hormone testing, 155
 - transport of, 108-109
 - European Multiple Endocrine Neoplasia Study Group recommendations, 71, 73-75
 - Euthyroid sick syndrome, thyroid function testing in, 27-28
 - Evolution, microbial, emerging infections from, 574-576
 - Exercise
 - B-type natriuretic peptide effects of, 263
 - in growth hormone provocative testing, 148-149
 - Exophiala* infections, 704
-
- ## F
-
- Familial medullary thyroid carcinoma, 56, 63-70
 - Fatty tissue. *See* Adipocytes and adipocytokines.
 - Fear, as barrier to error detection and reduction, 905-908
 - Filovirus infections, 773-774
 - Fish, *Streptococcus iniae* infections from, 599-600
 - Five percent random review, for postanalytic error detection, 933-934
 - 5S process, in lean production system, for error reduction, 880-890
 - Flavivirus infections, 781-783
 - Flucytosine, resistance to, 726
 - Folic acid metabolism inhibitors, 443
 - Food-borne infections, 567-569
 - gram-negative. *See* Gram-negative bacteria, in emerging enteric infections.
 - Free androgen index, 123-124
 - Free testosterone, 121-124

- Free thyroxine, measurement of
for screening, 22-23
in hyperthyroidism, 25-26
in hypothyroidism, 24-25
in nontyroidal illness, 28
methods for, 21
reference interval for, 23
- Free triiodothyronine, measurement of
in hyperthyroidism, 26
methods for, 21
reference interval for, 23
- Frozen sections, error detection in, 972-974
- Fungal infections, emerging, **691-719**
Acremonium, 700-701
Aspergillus, 695-696, 698-699
Bipolaris, 704
Blastoschizomyces capitatus, 707
Candida, 694-696, 704-705, 722-727
Cladophiala bantiana, 704
Cryptococcus neoformans, 694,
705-706, 723-727
Curvularia, 704
Dactylaria gallopavum, 704
dematiaceous molds, 704
Entomophthorales, 701-702
Exophiala, 704
Fusarium, 699, 729
Histoplasma capsulatum, 695, 702-703
host factors in, 692-696
cancer, 695-696
corticosteroids, 696
critical illness, 693
HIV infection, 694-695
immunodeficiency, 694-696
indwelling catheters, 693-694
transplantation, 695-696
hyalohyphomycoses, 697-698
in HIV infection, 694-695
Malassezia, 707
Mucorales, 701-702
Paecilomyces, 701
Penicillium marneffei, 695, 703
Pneumocystis jiroveci, 694, 696-697
Pseudallescheria boydii, 700
Ramichloridium, 704
Rhodotorula, 707
Scedosporium apiospermum, 700
Scopulariopsis, 701, 704
Trichosporon, 706-707
yeasts, 704-707
Zygomycetes, 693, 701-702
- Fusarium* infections, 699, 729
- G**
- Gas chromatography/mass spectrometry,
for testosterone, 120
- Gastroenteritis
food-borne, 567-569
gram-negative. *See* Gram-negative
bacteria, in emerging enteric
infections.
water-borne, 567-569
- Gatifloxacin
for respiratory tract infections, 480,
491-493
resistance to, 495
susceptibility testing of, 501-528
- GBV-C infections, transfusion-transmitted,
800
- Gemifloxacin
resistance to, 495
susceptibility testing of, 501-528
- Genetic factors, in antibiotic resistance, 403,
408-409, 425-426
- Giardiasis, 568
- Gliadin, antibodies to, in celiac disease, 288
- Global warming, emerging infections and,
563, 569-571
- Glucagon stimulation test, for growth
hormone, 151, 154
- Glucocorticoids. *See* Corticosteroids.
- Glucose, monitoring of, in insulin-induced
growth hormone testing, 149-150,
152-153
- Glutamic acid decarboxylase antibodies
in autoimmune polyglandular
syndromes, 295
in diabetes mellitus, 280-281
- Gluten enteropathy (celiac disease),
autoantibodies in, 287-289
- Gonadotropin-releasing hormone,
age-related changes in, 127-130
- Gonads, dysfunction of, 112
- Graft-versus-host disease, fungal infections
in, 695
- Gram-negative bacteria
antibiotic-resistant, in pediatric
patients, **361-378**
clinical consequences of, 365-366
epidemiology of, 362-370
in chronic care facilities, 370-371
mechanisms of, 361-362
outbreaks of, 366-367
transmission of, 367-370
in emerging enteric infections, **605-626**
Aeromonas, 620-621

- Campylobacter*, 615-618
Escherichia coli, Shiga toxin-producing, 612-614
Plesiomonas shigelloides, 621-622
Salmonella, nontyphoidal, 609-612
Vibrio, 606-609. *See also* Cholera.
Yersinia enterocolitica, 618-620
- Gram-positive infections, emerging, **587-603**
 coagulase-negative staphylococci, 591-593
Staphylococcus aureus, 588-591
 streptococcal
 group A, 593-596
 group B, 596-598
 groups C and G, 598-599
Streptococcus iniae, 599-600
- Graves disease
 autoantibodies in, 6, 284-286
 hyperthyroidism in, 25-26
- Grepafloxacin, for respiratory tract infections, 481
- Growth hormone, **141-173**
 binding protein of, 165
 deficiency of
 clinical features of
 in adults, 144-146
 in children, 141-144
 genetic analysis in, 166
 diagnosis of
 adult, 144-146
 algorithm for, 166-169
 childhood, 141-144
 insulin-like growth factor I and, 159-166
 isoforms of, 156-157
 measurement of
 methodology for, 146, 157-159
 provocative testing in, 148-156
 arginine, 150-151, 153-155
 clonidine-induced, 151, 153
 L-DOPA, 150-151, 153-154
 exercise, 148-149
 glucagon, 151, 154
 growth hormone
 secretagogues, 151, 154
 growth hormone-releasing hormone, 151, 154-155
 insulin, 149-150, 152-153
 sex hormone priming in, 155
 spontaneous, 147-148

replacement of, monitoring with insulin-like growth factor I, 163
 structure of, 146

Growth hormone-binding protein, interfering in hormone immunoassays, 7

Growth hormone-releasing hormone, stimulation with, for growth hormone testing, 154-155

H

- Haemophilus influenzae*
 antibiotic-resistant
 in pneumonia, 539, 541, 544
 macrolides, 453, 457, 459, 461, 465
 mechanisms of, 430, 434, 440, 442-443
 pharmacokinetics and pharmacodynamics and, 487-488
 prevalence of, 419, 421-422, 495, 530, 532-535
 susceptibility testing of, 501-511, 515-517, 520-523
 infections due to, antibiotic therapy for
 dosing in, 490, 494-495
 time-dependent, 478-479
 susceptibility testing of, 501-511, 515-517, 520-523
- Hand antisepsis, for antibiotic-resistant Gram-negative bacteria transmission control, 366-367
- Hantavirus infections, 570, 774-776
- Hashimoto thyroiditis, autoantibodies in, 286-287
- Health Level Seven, 917
- Heart disorders, in children, ventricular B-type natriuretic peptide assays in, 259-260
- Heart failure, **235-274**
 causes of, 236-238
 clinical course of, 238-239
 compensations in, 238-241
 adverse consequences of, 239-240
 protection against, 240-241
 definition of, 235-236
 diagnosis of
 new tests needed for, 244-245
 traditional tools for, 243-244
 epidemiology of, 236
 impact on Americans, 236

Heart (continued)

- ventricular B-type natriuretic peptide
 - in assays for, 250-254
 - at point of care, 260-262
 - clinical uses of, 262-265
 - for acute management, 254
 - for chronic management, 254-255
 - for screening, 255-256
 - prognostic value of, 256-258
 - right heart, 255
 - with arrhythmias, 259
 - biology of, 241-243
 - disease severity correlation with, 246-250
 - N-terminal fragment of clinical applications of, 263-265
 - disease severity correlation with, 247-250
 - in acute coronary syndromes, 252-253
 - in chronic management, 254-255
 - in pediatric patients, 260
 - in screening, 255-256
 - natriuretic peptide correlation with, 245-246
 - prognostic value of, 258
 - receptors for, 242-243
 - structure of, 240-241
- Hematology, identification errors in, 989-990
- Hemolytic transfusion reactions, in identification errors, 983
- Hemolytic uremic syndrome, in *Escherichia coli* O157:H7 infections, 612-614
- Hemorrhagic colitis, in *Escherichia coli* O157:H7 infections, 613-614
- Hemorrhagic fever
 - viral, 773-774
 - with renal syndrome, in hantavirus infections, 570, 774-776
- Henipavirus infections, 776-777
- Heparin, thyroid function testing effects of, 27
- Hepatitis A, transfusion-transmitted, 799-800
- Hepatitis B, transfusion-transmitted, 799-800
 - prevention of, 1027
- Hepatitis C
 - chronic manifestations of, 571
 - discovery of, 573
 - transfusion-transmitted, 800, 1027
- Hepatitis D, transfusion-transmitted, 799
- Hepatitis E, transfusion-transmitted, 799-800
- Heterophile antibodies, interfering with hormone immunoassays, 4-6, 35
- Hexarelin stimulation test, for growth hormone, 154
- High-dose hook effect, in thyroglobulin assay, 34-35
- Highly complex point-of-care testing, 1000
- High-performance liquid chromatography, with electrochemical detection, for metanephrine, 88-89, 93-96
- Hirata syndrome (insulin autoimmune syndrome), autoantibodies in, 283
- Histomorphometry, in osteoporosis, 177
- Histoplasma capsulatum* infections, 695, 702-703
- HIV infection. *See* Human immunodeficiency virus infection.
- HLAs. *See* Human leukocyte antigens.
- Hormone(s). *See* Endocrine disorders; *specific hormones*.
- Hormone immunoassays, interferences in, 1-18
 - autoantibodies, 6-7
 - binding proteins, 7-8
 - competitive, 1-2
 - cross-reactivity, 8
 - detection and correction of, 10-11
 - heterophile antibodies, 4-6, 35
 - immunometric, 3-4
 - matrix effects, 8-9
 - medical significance of, 11-13
 - rheumatoid factor, 9-10
- hsp65* gene sequencing, for mycobacterial identification, 652
- Human antianimal (heterophile) antibodies, interfering with hormone immunoassays, 4-6, 35
- Human chorionic gonadotropin, immunoassay for, interference in, 11-12
- Human herpes virus infections, transfusion-transmitted, 801-802

- Human immunodeficiency virus infection**
drug-resistant, 773
emergence of, 560, 565-566
fungal infections in, 694-695
leishmaniasis in, 764
microsporidiosis in, 743
parasitic infections in, 740-744
prevention of, blood supply testing for, 1027
sexual behavior and, 565-566
toxoplasmosis in, 740-742
transfusion-transmitted, 800-801
- Human leukocyte antigens**
in autoimmune polyglandular syndromes, 293-295
in celiac disease, 287-288
in diabetes mellitus, 276, 283
in Graves disease, 285
in thyroiditis, 286
- Human papillomavirus infections, detection of, in cervical cancer screening, 950, 952, 956-959**
- Human T-lymphotropic virus infections, transfusion-transmitted, 801**
- Hyalohyphomycoses infections, 697-698**
- Hydatid disease, alveolar, 828-829**
- Hydrophobic interaction chromatography, for insulin-like growth factor I, 159**
- 11 β -Hydroxylase, deficiency of, 112-113**
- 21-Hydroxylase**
antibodies to
in Addison disease, 290-292
in polyglandular syndromes, 306
deficiency of, 112-113
- 3- β -Hydroxysteroid dehydrogenase, antibodies to, in ovarian autoimmunity, 292**
- Hyperaldosteronism, primary, 109-110**
- Hyperandrogenism, 112**
- Hyperparathyroidism**
in multiple endocrine neoplasia type 2, 63
surgery for, intraoperative monitoring in, 204-212
- Hyperthyroidism**
in Graves disease, 25-26, 284-287
thyroid function testing in, 25-26
- Hypoglycemia, insulin-induced, for growth hormone deficiency testing, 149-150, 152-153**
- Hypogonadism, 112**
- Hypoparathyroidism, in autoimmune polyglandular syndromes, 293-294, 305**
- Hypophysitis, lymphocytic, autoantibodies in, 295-296**
- Hypothalamic-pituitary axis, dysfunction of, growth hormone deficiency in, 143-145**
- Hypothyroidism**
autoimmune, ovarian autoimmunity with, 291-292
in autoimmune thyroiditis, 286
thyroid function testing in, 24-25
-
- I**
- I-131 body scan, in thyroid carcinoma, thyroglobulin assay with, 40-41**
- IA-2 (protein tyrosine phosphatase-2, ICA512) antibodies, in diabetes mellitus, 281-282**
- Identification errors, 979-996**
conceptual framework for, 980-982
definitions of, 980-982
detection of, 974-975, 982-984
frequency of, 984-990
in anatomic pathology, 987-988
in chemistry, 989-990
in hematology, 989-990
in microbiology, 989-990
in point-of-care testing, 1007, 1015-1016
in transfusion medicine, 983, 986-987
informatics for, 927-929
public interest in, 990
reduction of, 991-994, 1028
regulations concerning, 990
taxonomy of, 980-982
underreporting of, 982-983
wristband, 968-970, 985-986, 991-992, 1028
- Immulate parathyroid hormone assays, 209-210**
- Immune response, to *Mycoplasma pneumoniae*, 631-632**
- Immunoassays**
for bone sialoprotein, 180
for deoxyypyridinoline, 181-183, 186
for hormones. *See* Hormone immunoassays.
for luteinizing hormone, 125-126
for osteocalcin, 188-189
for pyridinoline, 181-183, 186
for steroid hormones, 113-116

- Immunoassays (continued)**
for tartrate-resistant acid phosphatase, 180
for testosterone, 120, 122-123
- Immunoblot test**, for 3- β -hydroxysteroid dehydrogenase antibodies, in ovarian autoimmunity, 292
- Immunodeficiency**. *See also* Human immunodeficiency virus infection.
fungal infections in, 694-696
- Immunofluorescent antibody assay**, for West Nile virus, 783
- Immunoglobulin G**, measurement of, for *Trypanosoma cruzi*, 762
- Immunometric assays**
for calcitonin, in thyroid carcinoma, 67-68
for hormones, interferences in, 3-4
for insulin-like growth factor I, 159
for thyroglobulin, in thyroid carcinoma, 33
- Immunoprecipitation assay**
for adrenal hormone antibodies, 290-291
for glutamic acid decarboxylase antibodies, in diabetes mellitus, 280
for 3- β -hydroxysteroid dehydrogenase antibodies, in ovarian autoimmunity, 292
- Immunoradiometric assay**
for B-type natriuretic peptide, 245
for parathyroid hormone, 201, 203
- Indirect fluorescent antibody test**
for *Babesia*, 759
for *Ehrlichia*, 642
- Indirect immunofluorescent assay**
for adrenal hormone antibodies, 290
for transglutaminase antibodies, in celiac disease, 288
- Infection control**, for antibiotic resistance prevention, 334-336
- Infliximab**, fungal infections due to, 696
- Influenza**, 778
outbreaks of, 561
viral evolution in, 574-575
- Informatics**, in error detection and reduction, **913-943**
analytic, 929-933
Clinical Context Object Workgroup, 915-916, 928-929
- College of American Pathologists
Cancer Checklists, 914-915
decision support, 916, 927-928
electronic medical records, 916-917
Health Level Seven, 917
Institute of Medicine report
consequences and, 913-914, 935-937, 1023-1025
JCAHO in. *See* Joint Committee for Accreditation of Health Care Organizations.
Leapfrog Initiative, 918
logical observation identifiers names and codes, 918-919
on-line resources for, 926
postanalytic, 933-935
preanalytic, 927-929
Q-PROBES and Q-TRACKS in. *See* Q-PROBES and Q-TRACKS programs.
quality assurance and improvement in, 919-920
root cause analysis in. *See* Root cause analysis.
Six Sigma approach, 922-923, 1025-1026
Systemized Nomenclature of Medicine-Clinical Terms, 923-924
training in, 938-939
Transforming Health Care Quality through Information Technology, 924-925
Web-based systems for, 937-938
- Institute of Medicine**, health care quality reports of, 913-914, 935-937, 1023-1025
- Insulin**
antibodies to, 282-284
in growth hormone provocative testing, 149-150, 152-153
- Insulin autoimmune syndrome**, 283
- Insulin tolerance test**, for growth hormone deficiency, 149-150, 152-153
- Insulin-like growth factor I**
acid labile subunit of, 165-166
action of, 159
age variations of, 160
assays for, 159-162
free, 162-163
in growth hormone treatment monitoring, 163
problems with, 160-162
provocative, 165-166
standards for, 160-161
binding protein 2 of, 166

binding protein 3 of,
163-166
biologic variability of, 160

Insulin-like growth factor II, growth
hormone and, 166

Integrated pathology reports, 930-932

Intelligent Tutoring Systems, 934

Intensive care unit
antibiotic-resistant infections in. *See*
Critical illness, antibiotic-
resistant infections in.
fungal infections in, 693

Interleukin-6, in adipocytes, 226-227, 229

Interleukin-8, in adipocytes, 227

Interpretation errors, in anatomic
pathology, 849-850

Intracellular bacterial infections, emerging,
627-649
Anaplasma, 639-642, 811
Chlamydia pneumoniae, 633-638
Ehrlichia, 639-642, 811
list of, 629-630
Mycoplasma pneumoniae, 630-637
Rickettsiae, 642-645, 810-811

Iodide, thyroid function testing effects of,
26-27

Islet cell autoantibodies, 279-282

J

Joint Committee for Accreditation of
Health Care Organizations
patient identification goals of,
919-920, 990
point-of-care testing standards of, 999,
1001

K

Ketolides
as protein synthesis inhibitors, 437,
440
for respiratory tract infections, 481
macrolide-resistant, 463

Klebsiella infections
antibiotic-resistant, in pediatric
patients, 361-362
epidemiology of, 362-363, 365
outbreaks of, 366
transfusion-transmitted, 809

Klebsiella pneumoniae
in environment, 335-336

infections due to, antibiotic therapy
for, 483-484
resistance to, 348-349

Knowledge engineering, for
decision-making, 916

Kost's classification framework, for errors,
in point-of-care testing, 1005-1012

L

Labels, errors involving, 993, 1028. *See also*
Identification errors.

Laboratory Accreditation Program, patient
identification standards of, 990

Laboratory errors, definition of, 980-981

Laboratory identification errors. *See*
Identification errors.

Laboratory methods

for *Aeromonas*, 620-621
for *Anaplasma*, 641-642
for antifungal resistance, 722
for *Babesia*, 758-759
for bacterial blood component
contaminants, 810
for *Campylobacter*, 615-617
for *Chlamydomydia pneumoniae*,
634-635
for *Cryptosporidium parvum*, 745
for *Ehrlichia*, 641-642
for *Escherichia coli* O157:H7, 612-614
for filoviruses, 774
for fungi. *See specific fungi*.
for hantavirus, 776
for henipaviruses, 777
for HIV, 801
for *Leishmania*, 764-765
for malaria, 752-754
for metapneumovirus, 778
for monkeypox, 779
for mycobacteria. *See also specific*
mycobacteria.
biochemical reactions for
rapidly growing, 656-658
slowly growing, 654-655
for *Mycoplasma pneumoniae*, 632-633
for *Paragonimus*, 749
for parvovirus B19, 803
for *Plesiomonas shigelloides*, 621-622
for *Rickettsiae*, 643-645
for *Salmonella*, 609-610
for staphylococci, coagulase-negative,
591-593
for *Staphylococcus aureus*, 588-590
for streptococci
group A, 594-595
group B, 597

- Laboratory methods (*continued*)
group C and G, 598
for *Streptococcus iniae*, 600
for tapeworm infections, 768
for *Toxoplasma gondii*, 741-742
for *Trichomonas vaginalis*, 739
for *Trypanosoma brucei*, 756
for *Trypanosoma cruzi*, 762-763
for *Vibrio cholerae*, 607-608
for *Vibrio parahaemolyticus*, 608
for *Vibrio vulnificus*, 609
for West Nile virus, 783, 807-808
for *Yersinia enterocolitica*, 618-620
- Lapses, definition of, 982
- Larva migrans, in *Baylisascaris procyonis* infections, 746-748
- Latex antigen test, for *Cryptococcus neoformans*, 706
- Lean production methods, for error reduction, 865-899
evolution of, 866-867
in anatomic pathology
continuous workflow in, 883, 886-887, 889, 891-897
learning line for, 873-880
the 5S process in, 880-890
in health care system, 870, 872
in manufacturing industry, 866-871
- Leapfrog Initiative, 918
- Legionella pneumophila*, infections due to, antibiotic therapy for, 490, 494
- Leishmaniasis, 764-766
- Leptin, in adipocytes, 219-222, 229
- Levodopa (L-DOPA) stimulation test, for growth hormone, 150-151, 153-154
- Levofloxacin
for respiratory tract infections, 480-481, 491-493
susceptibility testing of, 501-528
- Leydig cell function, tests for, 119-131
free androgen index, 123-124
in aging, 126-130
luteinizing hormone, 124-126
sex hormone-binding globulin, 124
testosterone, 119-124
- Lincosamides, as protein synthesis inhibitors, 437
- Lipodystrophy, leptin deficiency in, 222
- Liquid chromatography-mass spectrometry
atmospheric pressure photoionization, for steroid hormones, 114-116
for metanephrine, 93-94, 96-100
- Litigation, fear of, as barrier to error detection and reduction, 907
- Logical observation identifiers names and codes, 918-919
- Long-term care, antibiotic resistance in. *See* Elderly persons, in institutions, antibiotic resistance in.
- Low-T₃ syndrome, thyroid function testing in, 27-28
- Luteinizing hormone, measurement of, in males, 124-126
- Lyme disease, 810-811
- Lymphocytic hypophysitis, autoantibodies in, 295-296
-
- M**
- Macrolides, 453-473. *See also specific drugs*, e.g., Erythromycin.
as protein synthesis inhibitors, 436-437
mode of action of, 453-454
resistance to
epidemiology of, 462-465
in *Streptococcus pneumoniae*, 421
mechanisms of, 454-461
spectrum of activity of, 454
structures of, 453-454
susceptibility testing of, 501-528
- Mad cow disease, 814-817
- Magnetic resonance imaging, for tapeworm infections, 768
- Malaria, 750-754
clinical features of, 751-752
current relevance of, 754
diagnosis of, 752-754
drug-resistant, 576
geographical expansion of, global warming and, 569-570
parasite life cycle in, 750-751
re-emergence of, 564-565
transfusion-transmitted, 812
- Malassezia* infections, 707
- Marburg virus infections, 773-774
- Mass spectrometry, for steroid hormones, 113-116
- Matrix effects
in hormone immunoassays, 8-9
in point-of-care testing, 1009
- mec* gene, in *Staphylococcus aureus*
methicillin resistance, 403-404, 412

- Medical Device Amendments of 1976, 1030
- Medical errors, definition of, 998
- Medullary thyroid carcinoma, 49-83
calcitonin secretion in, testing for, 66-68
C-cell hyperplasia in, 51-52
differential diagnosis of, 50
familial, 56, 63-70
Hirschsprung's disease with, 60-61
historical review of, 49-50
hormonal activity in, 51
in multiple endocrine neoplasia type 2, 54-63, 68-75
incidence of, 50
pathology of, 51-52
pheochromocytoma with, 61-62
RET gene mutations in, 57-60, 64-66
sporadic, 51-54
survival rate in, 51, 53
treatment of, 68-75
- Metabolic syndrome, testosterone deficiency in, 130, 132-134
- Metanephrines, testing for, in pheochromocytoma. *See* Pheochromocytoma, biochemical tests for, metanephrines.
- Metapneumovirus infections, 777-778
- Metastasis, from thyroid carcinoma, 32, 38-39, 52-53
- Methicillin
 Staphylococcus aureus resistance to.
 See *Staphylococcus aureus*, methicillin-resistant.
 susceptibility testing of, 409-412
- Methylation, ribosomal, in macrolide resistance, 454-457
- Microbiology, identification errors in, 989-990
- Micro-insulin autoantibody assay, 284
- Microscopy
 for *Cryptosporidium parvum*, 745
 for fungal identification. *See* specific fungi.
 for *Leishmania*, 764-765
 for malaria, 752-753
 for *Paragonimus*, 749
 for *Toxoplasma gondii*, 741-742
 for *Trichomonas vaginalis*, 739
 for *Trypanosoma brucei*, 756
 for *Trypanosoma cruzi*, 762
- Microsporidiosis, 742-744
- Migration, emerging infections and, 563-565
- Mineralocorticoids, 106
- Minimum inhibitory concentration, of antibiotics
 dosing based on, 332-333, 475, 478-479
 for vancomycin-resistant *Staphylococcus aureus*, 386-389
- Minnesota Society of Thoracic Surgeons database, 937
 on medical errors, 858
- Misidentification. *See* Identification errors.
- Mistakes, definition of, 982
- MK0677, for growth hormone, 154
- Model Performance Evaluation Program, 1030-1032
- Moderate-complexity point-of-care testing, 999-1001
- Monkeypox infections, 778-779, 830-831
- Monoclonal antibodies
 for luteinizing hormone assay, 125-126
 to bone alkaline phosphatase, 187-188
 to telopeptides, 181-185, 187
 to thyroglobulin, 31-33
- Moraxella catarrhalis*
 antibiotic-resistant
 pharmacokinetics and pharmacodynamics and, 488
 prevalence of, 419, 422, 434, 443
 susceptibility testing of, 501-507, 517-523
 infections due to, antibiotic therapy for, 478
 susceptibility testing of, 501-507, 517-523
- Mosquito-borne infections
 dengue fever, 808
 geographical expansion of, global warming and, 569-571
 malaria. *See* Malaria.
 Rift Valley Fever, 826-828
 viral encephalitis, 808
 West Nile virus, 781-783, 805-808
- Moxifloxacin
 resistance to, 495
 susceptibility testing of, 501-528
- MRSA. *See* *Staphylococcus aureus*, methicillin-resistant.

- MRSA-Screen, for methicillin resistance, 412
- Mucocutaneous candidiasis, in autoimmune polyglandular syndromes, 293-294, 305
- Mucorales infections, 701-702
- Multiple endocrine neoplasia type 2, 54-63, 68-75
calcitonin testing in, 66-68
classification of, 54-57
Hirschsprung's disease in, 57-60
hyperparathyroidism in, 63
pheochromocytoma in, 61-63
RET gene mutations in, 57-60, 64-66
treatment of, 68-75
- Multiple sclerosis, *Chlamydomydia pneumoniae* in, 638
- mur* genes, *Streptococcus pneumoniae*, 432
- Mutations, in antibiotic resistance development, 425-426
macrolides, 458-459
prevention of, 481-483
- Mycobacterial infections, emerging, **651-690**
Mycobacterium abscessus, 652, 654, 656-658
Mycobacterium alvei, 652-653, 656-658
Mycobacterium bohemium, 653, 659
Mycobacterium branderi, 654, 659
Mycobacterium brumae, 656-660
Mycobacterium celatum, 654, 660-661
Mycobacterium chesapeakei, 654, 661
Mycobacterium confluentis, 656-658, 661
Mycobacterium conspicuum, 654, 662
Mycobacterium doricum, 654, 662-663
Mycobacterium elephantis, 663
Mycobacterium genavense, 654, 663-664
Mycobacterium goodii, 656-658, 664-665
Mycobacterium haemophilum, 654, 665-666
Mycobacterium hassiacum, 656-658, 666
Mycobacterium heckeshornense, 654, 666-667
Mycobacterium heidelbergense, 667
Mycobacterium holsaticum, 656-658, 667-668
Mycobacterium immunogenicum, 656-658, 668
Mycobacterium interjectum, 654, 668-669
Mycobacterium intermedium, 654, 669
Mycobacterium kansasii, 654, 670
Mycobacterium lacus, 655, 670
Mycobacterium lentiflavum, 655, 671
Mycobacterium mageritense, 656-658, 671-672
Mycobacterium microti, 655, 672-673
Mycobacterium montefiorensis, 655, 673
Mycobacterium mucogenicum, 673-674
Mycobacterium murale, 656-658, 674
Mycobacterium neoaurum, 656-658, 674-675
Mycobacterium novacastrense, 656-658, 675
Mycobacterium palustre, 655, 675-676
Mycobacterium peregrinum, 656-658, 676
Mycobacterium pinnipedii, 655, 676-677
Mycobacterium septicum, 656-658, 677
Mycobacterium sherrisii, 655, 678
Mycobacterium shimoidei, 655, 678-679
Mycobacterium shottsii, 655, 679
Mycobacterium simiae-like organisms, 655, 679-680
Mycobacterium triplex, 655, 680-681
Mycobacterium tuberculosis subspecies *canettii*, 656-658, 681
Mycobacterium tuberculosis subspecies *caprae*, 655, 681-682
Mycobacterium tusciae, 655, 682-683
Mycobacterium vaccae, 656-658, 683
Mycobacterium wolinskyi, 656-658, 683-684
Mycobacterium tuberculosis, resistance to, pharmacokinetics and pharmacodynamics and, 489
Mycoplasma pneumoniae infections, 630-637
antibiotic therapy for, 490, 494
asthma and, 635-636
bronchiolitis and bronchiolitis obliterans and, 638
chronic obstructive pulmonary disease and, 636-637
cystic fibrosis and, 638
diagnosis of, 632-633
epidemiology of, 632
pathophysiology of, 630-632
-
- N**
- National Cancer Centers Network database, 937
on medical errors, 858
- National Report on the Quality of Laboratory Services, 1032-1033

- Natriuretic peptide, B-type natriuretic, in heart failure. *See under* Heart failure.
- Near misses, definition of, 981
- Neck dissection, radical, for medullary thyroid carcinoma, 53-54
- Necrotizing fasciitis, streptococcal, 595
- Neisseria meningitidis* infections, 561
- Neonatal intensive care unit, antibiotic-resistant Gram-negative bacteria in, 363-370
- Neonates, toxic shock syndrome-like exanthematous disease in, 591
- Neurocysticercosis, 766-768
- Neutropenia, fungal infections in, 695
- NH₂-terminal telopeptides, in osteoporosis, 181-187
- Nichols Advantage assay, for parathyroid hormone, 201-202
- Nipah virus infections, 776-777, 833-834
- Nonthyroidal illness, thyroid function testing in, 27-28
- Norepinephrine, tumors secreting. *See* Pheochromocytoma.
- Norfloxacin, for respiratory tract infections, 481-482
- Nosocomial infections, due to antibiotic-resistant Gram-negative bacteria, in pediatric patients, 361-378
- Nucleic acid test (NAT), for West Nile virus, 807-808
- Nursing homes, antibiotic resistance in. *See* Elderly persons, in institutions, antibiotic resistance in.

O

- Ob* gene product (leptin), in adipose tissue, 219-222, 229
- Obesity
- adiponectin in, 223-224
 - antibiotic pharmacokinetics and pharmacodynamics in, 487
 - leptin for, 222
 - plasminogen activator inhibitor type 1 in, 225-226, 229
 - testosterone deficiency in, 130, 132-134
- Omeprazole, for calcitonin testing, 66

- Ordering tests, errors in, 927-928, 967-968
- Organizational structure and culture, as barrier to error detection and reduction, 908-909
- Osteocalcin, in osteoporosis, 187-190
- Osteoporosis, 175-197
- biochemical markers for, 177-193
 - age-related changes in, 178-179
 - bone alkaline phosphatase isoenzyme, 187-188
 - bone sialoprotein, 180
 - collagen cross-links, 180, 182-187
 - deoxypyridinoline, 181-183, 186
 - osteocalcin, 187-190
 - pre-analytical issues in, 189, 191
 - principles of, 177-179
 - pyridinoline, 181-183, 186
 - tartrate-resistant acid phosphatase, 179-180, 182-183
 - telopeptides, 180, 182-187
 - urinary calcium, 179
 - uses of, 191-193
 - causes of, 176
 - development of, 175-176
 - diagnostic methods for, 177
 - epidemiology of, 176-177
- Ovary, autoimmune disease of, 291-292, 294

Oxacillin, susceptibility testing of, 409-412

P

- Paecilomyces* infections, 701
- Panton-Valentine leukocidin, as *Staphylococcus aureus* virulence factor, 407-409
- Pap testing. *See* Cervical cancer screening.
- Paragonimus* infections, 748-749
- Parasitic infections, emerging, 737-772
- Babesia*, 757-760, 812-813
 - Baylisascaris procyonis*, 746-748
 - common, 738-744
 - Cryptosporidium parvum*, 744-746
 - epidemic, 744-746
 - in blood supply, 757-763, 811-814
 - in HIV infection, 740-742
 - in travelers, 764-768
 - Leishmania*, 764-766
 - malaria. *See* Malaria.
 - microsporidiosis, 742-744
 - Paragonimus*, 748-749
 - rare, 746-749
 - Taenia*, 766-768

- Parasitic (continued)
Third World, 750-757. *See also*
Malaria.
Toxoplasma gondii, 740-742
Trichomonas vaginalis, 738-740
Trypanosoma brucei, 754-757
Trypanosoma cruzi, 760-763, 813-814
- Parathyroid hormone, 199-216
biochemistry of, 199-200
measurement of, 200-203
intraoperative, 204-212
rapid, 208-210
metabolism of, 199-200
- Parvovirus B19 infections, transfusion-transmitted, 802-803
- Patient identification errors. *See* Identification errors.
- Patient safety, error control in. *See* Error detection and reduction.
- Pediatric patients
antibiotic-resistant Gram-negative bacteria in, 361-378
clinical consequences of, 365-366
epidemiology of, 362-370
in chronic care facilities, 370-371
mechanisms of, 361-362
outbreaks of, 366-367
transmission of, 367-370
familial medullary thyroid carcinoma in, 63-70
growth hormone deficiency in. *See* Growth hormone, deficiency of.
heart disorders in, ventricular B-type natriuretic peptide assays in, 259-260
- Penicillin(s)
mechanism of action of, 428-429
resistance to, in *Streptococcus pneumoniae*, 419-420
susceptibility testing of, 501-528
- Penicillinases, 345-346
- Penicillin-binding proteins
of respiratory pathogens, 429-433
of *Staphylococcus aureus*, 403
- Penicillium marneffei* infections, 695, 703
- Pentagastrin, for calcitonin testing, 66-67
- Peptidases, in bacterial destruction, 428
- Peptidoglycan layer
of *Staphylococcus aureus*, vancomycin resistance and, 383-384, 392-396
of *Streptococcus pneumoniae*, 427-429
- Peroxidase-antiperoxidase method, for thyroglobulin, 31-32
- Pharmacokinetics and pharmacodynamics, of antimicrobial therapy for respiratory tract infections. *See under* Respiratory tract infections.
- Pheochromocytoma
biochemical tests for, 85-103
diagnostic value of, 86-91
metanephrines
characteristics of, 92-95
evolution of, 96-97
plasma-free, 95-96
specimens for, 98-99
tandem mass spectrometry in, 97-98
versus catecholamines, 91-92
in multiple endocrine neoplasia type 2, 61-63
- Pig tapeworm infections, 766-768
- Pittsburgh Regional Health Care Initiative, 870, 872
- Pituitary gland
dysfunction of, growth hormone deficiency in, 143-145, 166
lymphocytic hypophysitis of, 295-296
- Plasma renin activity, in hyperaldosteronism, 109-110
- Plasminogen activator inhibitor type 1, in adipocytes, 225-226, 229
- Plasmodium* infections. *See* Malaria.
- Plesiomonas shigelloides* infections, 621-622
- Pneumocandins, resistance to, 725
- Pneumococci. *See* *Streptococcus pneumoniae*.
- Pneumocystis jiroveci* infections, 694, 696-697, 725
- Pneumonia
amoxicillin/clavulanate for, 537-539, 541-544
due to methicillin-resistant *Staphylococcus aureus*, 409
epidemiology of, 529-530
- Pneumovirus infections, 777-778
- Point-of-care testing, 997-1022
adverse event reporting in, 1018
competence assessment in, 1014
definitions of, 998-1001
errors in, 1005-1010
causes of, 1002

- ethos for, 1012-1018
 - Kost's classification framework for, 1005-1012
 - latent conditions predisposing to, 1002-1005
 - standard safety model for, 1002-1003
 - moderate-complexity testing category of, 999-1001
 - operator training for, 1013
 - patient identification in, 1015-1016
 - proficiency testing in, 1014-1015
 - provider-performed microscopy testing category of, 999, 1001
 - result reporting in, 1016
 - specimen acceptability for, 1016
 - supervision of, 1014
 - waved testing category of, 998-999, 1001
- Polyclonal antibody(ies), to thyroglobulin, 31-32
- Polyenes, resistance to, 723
- Polyglandular/polyendocrine syndromes, autoimmune
- type 1, 293-294, **305-317**
 - autoimmune regulator in, 307-313
 - clinical features of, 305-306
 - tests for, 313-314
 - type 2, 294-295, 305
 - type 3, 305
- Polymerase chain reaction
- for *Babesia*, 760
 - for beta-lactamases, 354-355
 - for *Chlamydomphila pneumoniae*, 635
 - for *Ehrlichia*, 642
 - for emerging pathogen detection, 572-573
 - for filoviruses, 774
 - for hantavirus, 776
 - for henipaviruses, 777
 - for *Leishmania*, 765
 - for malaria, 753
 - for *mec* gene, 412
 - for metapneumovirus, 778
 - for *Mycoplasma pneumoniae*, 633
 - for *Pneumocystis jiroveci*, 697
 - for Rickettsiae, 643-645
 - for SARS-coronavirus, 781
 - for thyroglobulin mRNA, 38-39
- Poole Therapeutic Outcome Model, for antibiotic efficacy evaluation, 492
- Population demographics and distribution, in emerging infections, 562-565
- Postanalytic errors
- definition of, 981
 - detection of, Q-PROBES and Q-TRACKS programs for, 974-975
 - frequency of, 1026
 - in point-of-care testing, 1006, 1009-1012
 - informatics for, 933-935
- Post-antibiotic effects, of antibiotics, 477
- Postlaboratory errors, definition of, 981
- Potassium analysis, potential errors in, 1029
- Poxvirus infections, 778-780
- Preanalytic errors
- definition of, 981
 - detection of, Q-PROBES and Q-TRACKS programs for, 967-972
 - frequency of, 1026
 - in point-of-care testing, 1005-1008, 1011
 - reduction of, 1027-1029
 - informatics for, 927-929
- Prelaboratory errors, definition of, 980
- Premature ovarian failure, in ovarian autoimmunity, 291-292, 294
- Preventable adverse event, definition of, 998
- Prion diseases, transfusion-transmitted, 814-817
- Process improvement, 919-920
- Proficiency testing, in point-of-care testing, 1014-1015
- Progesterone, 108
- Progestins, 108
- Prolactin, antibodies to, 7
- PROPI protein, defects of, growth hormone deficiency in, 166
- Propranolol, thyroid function testing effects of, 26
- Prostate-specific antigen, immunoassay for, interference in, 12
- Protein synthesis inhibitors, in resistance, 436-440
- Protein tyrosine phosphatase-2 (ICA512/IA-2) autoantibodies, in diabetes mellitus, 281-282
- Provider-performed microscopy testing, 999, 1001

Pseudallescheria boydii infections, 700

Pseudohyperkalemia, errors producing, 1029

Pseudomonas aeruginosa
in environment, 335-336
infections due to, antibiotic therapy for, 483

Pseudomonas infections
antibiotic-resistant, in pediatric patients, 361, 365-367
transfusion-transmitted, 809

Public health systems, breakdown of, emerging infections due to, 576-578

Public interest, in identification errors, 990

Pulsed-field gel electrophoresis, for beta-lactamase identification, 354

Puromycin, as protein synthesis inhibitor, 436

Pyridinoline, in osteoporosis, 181-183, 186

Q

Q-PROBES and Q-TRACKS programs, 965-978
description of, 920-921, 965-967, 1030-1031
in analytical phase of testing, 972-974
in anatomic pathology error detection, 851, 854-856, 858
in postanalytical phase of testing, 974-975
in preanalytical phase of testing, 967-972

Quality assurance, 919-920

Quality control, in point-of-care testing, 1003, 1009

Quality improvement, 919-920. *See also* Q-PROBES and Q-TRACKS programs.

Quality management, in cervical cancer screening, in developing countries, 945-949
of cytology facilities, 950-953
of noncytologic methods, 956-959

Quality System Regulation of 1996, 1030

Quick-IntraOperative Intact PTH assay, 209-210

Quinolones
for respiratory tract infections, 480-482
resistance to, 442
susceptibility testing of, 501-528

R

Raccoons, *Baylisascaris procyonis* in, 746-748

Radio frequency identification systems, 927, 993

Radioassay, for glutamic acid decarboxylase antibodies, in diabetes mellitus, 280

Radiobinding assay
for 3- β -hydroxysteroid dehydrogenase antibodies, in ovarian autoimmunity, 292
for ICA512 autoantibodies, in diabetes mellitus, 282
for transglutaminase antibodies, in celiac disease, 288-289

Radioimmunoassays
for adipocytokines, 228
for hormones, interferences with, 2
for insulin antibodies, 282-283
for thyroglobulin, in thyroid carcinoma, 32-33

Radiotherapy, for medullary thyroid carcinoma, 54

Ramichloridium infections, 704

Rearranged in transfection gene. *See* RET gene.

Record-keeping, in point-of-care testing, 1017

Red tagging, in lean production system, 880-881

Redundancy methods, for identification error reduction, 994

Reduviidae, in American trypanosomiasis transmission, 760-763, 813-814

Re-emerging infections, examples of, 560-561

Reference Information Model, for data transmission, 917

Regulations, on identification errors, 990

Reporting. *See also* Communication; Informatics.
of errors
anatomic pathology, 849-850
failure to, 903-905
identification, 982-983
in point-of-care testing, 1018
of results
addenda and amendments in, 929-930
in point-of-care testing, 1016

- integrated, 930-932
standardized, 914-915
synoptic, 932-933
- Reporting systems, errors in, 974-975
- Resistance
antifungal. *See* Antifungal agents, resistance to.
antimicrobial. *See* Antimicrobial resistance.
- Resistin, in adipocytes, 224, 229
- Respiratory tract infections
antimicrobial therapy for
amoxicillin/clavulanate in, 536-544
pharmacokinetics and pharmacodynamics of, 475-500
animal models of, 483-487
combination, 487
concentration-dependent killing, 480-481
for optimization, 489-496
mutant prevention concentration, 481-483
obesity and, 487
plasma vs. tissue concentrations, 485-487
principles of, 476-480
resistance and, 487-489
epidemiology of, 529-530
- Respiratory tract pathogens. *See also specific organisms.*
antibiotic-resistant, 417-451
mechanisms of, 427-443, 530-536
beta-lactamases, 427-436
DNA replication inhibition, 441-443
folic acid metabolism inhibition, 443
protein synthesis inhibition, 436-440
prevalence of, 419-422, 530-536
selection of, 423-426
- Restriction fragment length polymorphism testing, for mycobacteria, 651-652
- RET gene, mutations of
in multiple endocrine neoplasia type 2, 57-60
in pheochromocytoma, 61-62
management based on, 68-74
testing for, 64-66
- Retroviral infections,
transfusion-transmitted, 800-801
- Reverse transcription-polymerase chain reaction, for thyroglobulin mRNA, 38-39
- Rheumatoid factor, interfering in hormone immunoassays, 9-10
- Rhinosinusitis
amoxicillin/clavulanate for, 536-537, 539-544
epidemiology of, 529-530
- Rhodotorula* infections, 707
- Ribosomal target site modification, in macrolide resistance, 454-458
- Rickettsial infections, 642-645, 810-811
- Rift Valley Fever, 826-828
- RNA analysis, 16s rRNA, for mycobacteria, 651
- Roche electrochemiluminescent method, for B-type natriuretic peptide, 245
- Rocky Mountain spotted fever, 642-645, 811
- Root cause analysis, for errors, 921-922
in anatomic pathology, 857
in cervical cancer screening, 953-956
- Roxithromycin, for respiratory tract infections, 486
-
- S**
- Saccharomyces cerevisiae*, resistance in, 725
- "Safe Practices for Better Health Care: A Consensus Report," 918
- Safety, patient, error control in. *See* Error detection and reduction.
- Salmonella* infections
food-borne, 567
nontyphoidal, 609-612
clinical features of, 610-611
diagnosis of, 611
epidemiology of, 610
microbiology of, 609-610
resistance in, 611-612
treatment of, 611-612
- Salmonella* serotype Typhimurium infections, travel-associated, 568
- Sandfly, in *Leishmania* transmission, 764-765

- SARS (severe acute respiratory syndrome)-coronavirus infections, 576-577, 780-781, 803-804, 834-835
- Scantibodies assay, for parathyroid hormone, 202-203
- Scedosporium* infections, 700, 729-730
- Schmidt syndrome (autoimmune polyglandular syndrome type 2), 294-295, 305
- Scopulariopsis* infections, 701, 704
- Second opinion review, for postanalytic error detection, 933-934
- SEN virus infections, transfusion-transmitted, 800
- Sentinel events, definition of, 981
- Sepsis, from contaminated transfusion components, 808-810
- Serratia* infections
antibiotic-resistant, in pediatric patients, 361
colonization by, 369
epidemiology of, 362-363
outbreaks of, 366
transfusion-transmitted, 809
- Serum-concentration-time profile, of antibiotics, 475
- Seventh International Workshop on Multiple Endocrine Neoplasia recommendations, 70-73
- Severe acute respiratory syndrome (SARS), 576-577, 780-781, 803-804, 834-835
- Sex hormone-binding globulin
age-related changes in, 127
in obesity, 132-133
interfering in hormone immunoassays, 7-8
measurement of, 124
- Sexual behavior, emerging infections and, 565-566
- Shiga toxin-producing *Escherichia coli*. *See* *Escherichia coli* infections, O157:H7.
- Shionogi immunoradiometric assay, for B-type natriuretic peptide, 245
- Short stature, in growth hormone deficiency, 143-144
- Sialoprotein, bone, in osteoporosis, 180
- Single sign-on system, 928-929
- Six Sigma approach, to error analysis, 922-923, 1025-1026
- Skilled nursing facilities, antibiotic resistance in. *See* Elderly persons, in institutions, antibiotic resistance in.
- Skin infections, due to methicillin-resistant *Staphylococcus aureus*
examples of, 404, 406
genetic markers for, 408-409
outbreaks of, 406-407
virulence factors of, 408
- Sleeping sickness (African trypanosomiasis), 754-757
- Slips, definition of, 982
- Smallpox, 780
- Sodium iodide cotransporter, antibodies to in Graves disease, 285
in thyroiditis, 287
- Soft-tissue infections, due to methicillin-resistant *Staphylococcus aureus*
examples of, 404, 406
genetic markers for, 408-409
outbreaks of, 406-407
virulence factors of, 408
- Somatomedin-C. *See* Insulin-like growth factor I.
- Special procedure reports, 930-932
- Specimens
acceptability of, in point-of-care testing, 1016
acquisition of, errors in, 970-972
identification errors involving. *See* Identification errors.
small sample volume of, in point-of-care testing, 1008
- Staphylococcal infections, emerging
coagulase-negative, 591-593
group A, 593-596
group B, 596-598
groups C and G, 598-599
- Staphylococcus aureus*
infections due to
antibiotic therapy for, 401, 478-480
antibiotic-resistant, 442, 576
emerging, 588-591
transfusion-transmitted, 809
methicillin-resistant, 401-416
clinical significance of, 404-406
epidemiology of, 402-403
genetics of, 403, 408-409
mechanism of, 403-405

- outbreaks of, 406-407
- rapid detection of, 412
- susceptibility testing of, 409-411
- virulence factors of, 407-408
- vancomycin-intermediate, 383
- vancomycin-resistant, **379-400**
 - COLVA strain, 392-396
 - development of, 384-385
 - genetic basis of, 389-392
 - mechanisms of, 383-384
 - Michigan isolate, 389-390
 - Pennsylvania isolate, 390-392
 - physiologic basis of, 392-396
 - resistant enterococci and, 380-382
 - susceptibility testing of, 385-389
- Staphylococcus epidermidis* infections,
 - transfusion-transmitted, 809
- STAT-IntraOperative-Intact-PTH kit, 209
- Stem cell transplantation, fungal infections in, 695
- Steroid 17 α -hydroxylase, antibodies to
 - in Addison disease, 290-291
 - in polyglandular syndromes, 306
- Steroid cell autoantibodies, in ovarian autoimmunity, 291-292
- Steroid hormones, **105-118**. *See also specific hormones.*
 - androgens, 107
 - clinical abnormalities of, 109-113
 - estrogens, 108
 - fate of, 108-109
 - glucocorticoids, 106-107
 - measurement of, 113-116
 - mineralocorticoids, 106
 - progestins, 108
 - transport of, 108-109
- Streptococcus agalactiae* infections, 596-598
- Streptococcus dysgalactiae* infections, 598-599
- Streptococcus epidermidis* infections, 592-593
- Streptococcus equi* infections, 598-599
- Streptococcus* infections
 - of newborn, prophylaxis of, antibiotic resistance development in, 363-364
 - transfusion-transmitted, 809
- Streptococcus iniae* infections, 599-600
- Streptococcus pneumoniae*
 - antibiotic-resistant, 417
 - in pneumonia, 537-544
 - in rhinosinusitis, 536-537
 - macrolides, 453, 457, 459-464
 - mechanisms of, 427-433, 439-440, 442-443
 - pharmacokinetics and pharmacodynamics and, 487-488
 - prevalence of, 419-422, 495, 530, 533-536
 - susceptibility testing of, 501-515, 519-523
- infections due to, antibiotic therapy for
 - animal models of, 483, 485-486
 - concentration-dependent killing in, 480-481
 - dosing in, 490-496
 - time-dependent, 478-480
 - susceptibility testing of, 501-515, 519-523
- Streptococcus pyogenes*
 - infections due to, 483, 486, 593-596
 - macrolide-resistant, 453, 457, 459, 461, 463, 465
- Streptogramins, as protein synthesis inhibitors, 437
- Sulfamethoxazole, as folic acid metabolism inhibitor, 443
- Supervision, in point-of-care testing, 1014
- Surgery, fungal infections in, 693
- Surgical pathology, identification errors in, 970, 987-988
- Susceptibility testing. *See also* Antimicrobial resistance.
 - for antibiotic dose optimization, 332-333
 - of antifungal agents, 722
 - of *Haemophilus influenzae*, 501-511, 515-517, 520-523
 - of *Moraxella catarrhalis*, 501-507, 517-523
 - of *Staphylococcus aureus*
 - methicillin-resistant, 409-412
 - vancomycin-resistant, 385-389
 - of *Streptococcus pneumoniae*, 501-515, 519-523
- Systemized Nomenclature of Medicine-Clinical Terms, 923-924

T

- Taenia* infections, 766-768
- Tanapox infections, 779-780

- Tapeworm infections
 Echinococcus multilocularis, 828-829
 Taenia, 766-768
- Tartrate-resistant acid phosphatase, in osteoporosis, 179-180, 182-183
- Telithromycin, resistance to, mechanisms of, 457, 460
- Telopeptides, in osteoporosis, 180, 182-187
- Temafloxacin, for respiratory tract infections, 481
- Terminology, Systemized Nomenclature of Medicine-Clinical Terms, 923-924
- Testosterone, 107
 measurement of, 112, **119-139**
 bioavailable, 123
 for Leydig cell evaluation, 119-124
 free, 121-124
 in obesity, 130, 132-134
 total, 119-121
 transport of, 108-109
- Tetracyclines, as protein synthesis inhibitors, 436, 440
- Tetrahydrofolate reductase inhibitors, 443
- Thymus, autoimmune regulator protein in, 313
- Thyroglobulin, **29-47**
 antibodies to
 in autoimmune polyglandular syndromes, 294
 in Graves disease, 6, 285
 in thyroid carcinoma, 41-42
 in thyroiditis, 286-287
 interfering with assays, 36-38
 measurement of
 in serum, 32-38
 in thyroid carcinoma, 29, 31-32, 34, 38-42
 in tissue specimens, 31-32
 mRNA, 38-39
 physiology of, 29-31
 structure of, 29-30
 variant forms of, 35-36
- Thyroid cell bioassay, for thyroid-stimulating hormone receptor antibodies, 285-286
- Thyroid function testing, **19-28**
 drug effects on, 26-27
 in elderly persons, 24
 in hyperthyroidism, 25-26
 in hypothyroidism, 24-25
 in nonthyroidal illness, 27-28
 normal function and, 19-21
 procedures for, 21-22
 reference intervals for, 23
 screening, 22-23
- Thyroid gland
 autoimmune disease of, 284-287
 in autoimmune polyglandular syndromes, 305
 ovarian autoimmunity with, 291-292
 carcinoma of
 medullary. *See* Medullary thyroid carcinoma.
 thyroglobulin measurement in, 29, 31-32, 34, 38-42
 functional testing of. *See* Thyroid function testing.
- Thyroid peroxidase, antibodies to
 in autoimmune polyglandular syndromes, 294
 in Graves disease, 285
 in thyroiditis, 286-287
- Thyroidectomy, for medullary thyroid carcinoma, 53-54
 prophylactic, 67-75
- Thyroiditis, autoimmune, autoantibodies in, 286-287
- Thyroid-stimulating autoantibody, in Graves disease, 285
- Thyroid-stimulating hormone receptor, antibodies to, in Graves disease, 285-286
- Thyrotropin, measurement of
 drug effects on, 26-27
 for screening, 22-23
 in elderly persons, 24
 in hyperthyroidism, 26
 in nonthyroidal illness, 27-28
 interference in, 12-13
 methods for, 21-22
 reference interval for, 23
- Thyroxine
 measurement of, 21
 physiology of, 19-21
- Thyroxine-binding globulin, interfering in hormone immunoassays, 7
- Tick-borne infections
 Anaplasma, 639-642, 811
 Babesia, 757-760, 812-813
 bacterial, 810-811
 Borrelia, 810-811
 Ehrlichia, 639-642, 811
 ricketsial, 642-645, 810-811

- "To Err is Human: Building a Safer Health System," 901, 913, 998, 1024
- Topoisomerases, inhibitors of, 441-442
- Total thyroxine, measurement of
methods for, 21
reference interval for, 23
- Total triiodothyronine, measurement of
methods for, 21
reference interval for, 23
- Toxic shock syndrome
staphylococcal, 407-408, 589-591
streptococcal, 595-596
- Toxoplasmosis, 740-742
- Toyota lean production system, 866-871
- Training, for point-of-care testing, 1003, 1013
- Transforming Health Care Quality through Information Technology, 924-925
- Transfusion(s)
HIV detection in, 1027
identification errors in, 983, 986-987
specimen collection errors in, 971-972
- Transfusion-transmitted infections,
emerging, 797-823
bacterial, 808-810
Creutzfeldt-Jacob disease, 814-817
enteroviruses, 804-805
historical background of, 797-799
human herpes viruses, 801-802
human immunodeficiency virus, 800-801
human T-lymphotropic virus, 801
mosquito-borne viruses, 805-808
parasitic, 757-763, 811-814
parvovirus B19, 802-803
retrovirus, 800-801
SARS, 803-804
tick-borne, 810-811
viral hepatitis, 799-800
West Nile virus, 805-808
- Transglutaminase, antibodies to, in celiac disease, 288-289
- Transplantation, fungal infections in, 695-696
- Trauma, fungal infections in, 693
- Travelers, emerging infections carried by, 577
cholera, 568-569
in airplanes, 564
parasitic, 764-768
- Triazoles, resistance to, 724-725
- Trichomoniasis, 738-740
- Trichosporon* infections, 706-707, 723, 727
- Triiodothyronine
measurement of, 21, 27-28
physiology of, 19-21
- Trimethoprim, as folic acid metabolism inhibitor, 443
- Trimethoprim-sulfamethoxazole
resistance to, 495
susceptibility testing of, 501-528
- Tropheryma whippelii*, discovery of, 573
- Troponin, immunoassay for, interference in, 13
- Trypanosomiasis
African, 754-757
American (Chagas' disease), 760-763, 813-814
- Tsetse fly, in African trypanosomiasis transmission, 754-757
- TT virus infections,
transfusion-transmitted, 800
- Tuberculosis, drug resistance in, 489
- Tumor markers, immunoassay for, interference in, 12
- Tumor necrosis factor- α , in adipocytes, 224-225, 229
- Turbo intact PTH assay, 209-210
- Tyrosine hydroxylase, antibodies to, in autoimmune polyglandular syndromes, 294
-
- ## U
- Uncertainty, intolerance of, 903-905
- Urine culture, specimen collection for, errors in, 971
-
- ## V
- Vaccination, refusal of, emerging infections and, 567
- Vaccinia virus infections (smallpox), 780
- Vancomycin, resistance to
in enterococci, 380-382, 575
in *Staphylococcus aureus*. See *Staphylococcus aureus*, vancomycin-resistant.
- Vanillylmandelic acid, testing for, in pheochromocytoma, diagnostic value of, 87, 90-91

Variant Creutzfeldt-Jacob disease,
transfusion-transmitted, 814-817

Velogene Rapid MRSA Identification
Assay, for methicillin resistance, 412

Ventricular B-type natriuretic peptide, in
heart failure. *See under* Heart failure.

Vibrio cholerae infections. *See* Cholera.

Vibrio parahaemolyticus infections, 608

Vibrio vulnificus infections, 608-609

Viral infections, emerging, **773-792**

drug-resistant HIV, 773

filoviruses, 773-774

hantavirus, 570, 774-776

henipavirus, 776-777

influenza, 561, 574-575, 778

metapneumovirus, 777-778

poxviruses, 778-780

severe acute respiratory syndrome
(SARS), 576-577, 780-781,
803-804, 834-835

West Nile virus, 781-783, 805-808

Virulence factors, *Staphylococcus aureus*,
407-408

Visceral leishmaniasis, 764-766

Vitek systems, for methicillin susceptibility,
410-411

W

Waived testing, point-of-care, 998-999,
1001

Waste, in anatomic pathology procedures,
reduction of, 883, 886-887

Water-borne infections, 567-569
gram-negative. *See* Gram-negative
bacteria, in emerging enteric
infections.

Web-based systems, for error detection and
reduction, 858, 937-938

West Nile virus infections, 781-783,
805-808

Wet preparations, for *Trichomonas*
vaginalis, 739

Whole slide interinstitutional review, for
postanalytic error detection, 933-934

Williams micro-insulin autoantibody assay,
284

Workflow, continuous, in lean production,
for error reduction, 883, 886-887, 889,
891-897

Wristband identification errors, 968-970,
985-986, 991-992, 1028

X

Xenodiagnosis, for *Trypanosoma cruzi*, 762

Y

Yeast infections, emerging, 704-707

Yersinia enterocolitica infections, 618-620,
809

Z

Zoonoses. *See also* Mosquito-borne
infections; Tick-borne infections.
emerging, **825-838**

alveolar echinococcosis, 828-829

Baylisascaris procyonis, 746-748

brand new agents in, 833-835

Ebola virus, 773-774, 832-833

hantavirus, 570, 774-776

henipavirus infections, 776-777

in new areas, 826-829

in new species, 829-833

Leishmania, 764-765

monkeypox infections, 778-779,
830-831

Nipah virus, 776-777, 833-834

Rift Valley Fever, 826-828

severe acute respiratory
syndrome (SARS),
576-577, 780-781, 803-804,
834-835

tanapox infections, 779-780

tick-borne. *See* Tick-borne
infections.

Zygomycetes infections, 693, 701-702, 723

